NEW YORK–(BUSINESS WIRE)–Zamansky LLC announces that it is investigating Zafgen, Inc.
(NASDAQ:ZFGN) (“Zafgen” or the “Company”) for potential breaches of
fiduciary duties by its officers and board of directors. If you are a
shareholder of Zafgen who still holds your shares, please contact our
firm for information.
It has recently emerged from public filings that Zafgen has received a
letter from the U.S. Food and Drug Administration (“FDA”) citing
possible cardiovascular safety risks associated with the clinical trial
of a new type 2 diabetes drug ZGN-1061 as the reason for placing a
clinical hold on the trial.
According to Jake Zamansky, investment fraud attorney, part of the
fiduciary duties owed by Zafgen’s officers and directors to the Company
and its shareholders is the obligation to avoid such potentially
What Zafgen Shareholders Can Do
If you are a current shareholder of Zafgen who still holds your stock,
please contact us to review or discuss your legal rights. You may,
without obligation or cost to you, email email@example.com
or call the law firm at (212) 742-1414.
About Zamansky LLC
Zamansky LLC is a leading investment fraud law firm with experience
handling securities, hedge fund, ERISA and other shareholder class
action and derivative litigation. We are investment fraud attorneys who
represent both individual and institutional investors. Our practice is
nationally recognized for our ability to aggressively prosecute cases
and recover investment losses.
To learn more about Zamansky LLC, please visit our website, http://www.zamansky.com.
50 Broadway – 32nd Floor
New York, NY 10004